<!-- Context: Exclusion Criteria -->


# Page 11


<!-- BOUNDARY_START type="paragraph" id="p11_text_1" page="11" char_count="25" word_count="3" breadcrumbs="Exclusion Criteria" -->
Protocol No.: CTJ301UC201
<!-- BOUNDARY_END type="paragraph" id="p11_text_1" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_2" page="11" char_count="63" word_count="8" breadcrumbs="Exclusion Criteria" -->
<1500/μL); or lymphopenia (absolute lymphocyte count <500/μL) .
<!-- BOUNDARY_END type="paragraph" id="p11_text_2" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_3" page="11" char_count="129" word_count="19" breadcrumbs="Exclusion Criteria" -->
Moderate to severe anaemia (haemoglobin <9 g/dL), or thrombocytopenia (platelet count <75 000/μL) , or serum creatinine >2 mg/dL.
<!-- BOUNDARY_END type="paragraph" id="p11_text_3" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_4" page="11" char_count="91" word_count="12" breadcrumbs="Exclusion Criteria" -->
Autoimmune disease besides UC, with the exceptions of Sjogren's syndrome or hypothyroidism.
<!-- BOUNDARY_END type="paragraph" id="p11_text_4" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_5" page="11" char_count="139" word_count="19" breadcrumbs="Exclusion Criteria" -->
Clostridium  (C.)  difficile  positive  at  screening  visit  or  treated  for  C.  difficile  within  the  4 weeks prior to Randomization.
<!-- BOUNDARY_END type="paragraph" id="p11_text_5" -->

<!-- BOUNDARY_START type="code" id="p11_code_1" page="11" language="javascript" breadcrumbs="Exclusion Criteria" -->
```javascript
Known clinically relevant chronic liver disease. Impaired hepatic function in the absence of a diagnosis of primary sclerosing cholangitis (serum transaminases >2.5 x upper limit of normal [ULN],  alkaline  phosphatase  >2.5  x  ULN,  or  abnormalities  in  synthetic  liver  function  tests judged  by  the  investigator  to  be  clinically  significant),  or  a  diagnosis  of  primary  sclerosing cholangitis, serum transaminases >3 x ULN, alkaline phosphatase >3 x ULN, or abnormalities in synthetic liver function tests (total bilirubin >1.5 x ULN) judged by the investigator to be clinically significant.
```
<!-- BOUNDARY_END type="code" id="p11_code_1" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_6" page="11" char_count="76" word_count="12" breadcrumbs="Exclusion Criteria" -->
Serious underlying disease other than UC in the opinion of the investigator.
<!-- BOUNDARY_END type="paragraph" id="p11_text_6" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_7" page="11" char_count="99" word_count="18" breadcrumbs="Exclusion Criteria" -->
History of drug addiction within the last 1 year or current drug addiction or use of illicit drugs.
<!-- BOUNDARY_END type="paragraph" id="p11_text_7" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_8" page="11" char_count="77" word_count="15" breadcrumbs="Exclusion Criteria" -->
Any indication of the regular use of more than 40 grams of alcohol every day.
<!-- BOUNDARY_END type="paragraph" id="p11_text_8" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_9" page="11" char_count="50" word_count="9" breadcrumbs="Exclusion Criteria" -->
Smokers who smoke more than 10 cigarettes per day.
<!-- BOUNDARY_END type="paragraph" id="p11_text_9" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_10" page="11" char_count="115" word_count="17" breadcrumbs="Exclusion Criteria" -->
Known concurrent acute or chronic viral hepatitis B or C infection or human immunodeficiency virus (HIV) infection.
<!-- BOUNDARY_END type="paragraph" id="p11_text_10" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_11" page="11" char_count="329" word_count="48" breadcrumbs="Exclusion Criteria" -->
Presence or history of active tuberculosis (TB) or latent TB infection, defined as 1) a positive QuantiFERON-TB  Gold  test  at  Screening,  or  2)  a  positive  T-spot  test  within  4  weeks  of Randomisation  and  evidence  of  current  or  previous  pulmonary  tuberculosis  by  chest  X-ray within 12 weeks of Randomisation.
<!-- BOUNDARY_END type="paragraph" id="p11_text_11" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_12" page="11" char_count="133" word_count="17" breadcrumbs="Exclusion Criteria" -->
Positive  immunoglobulin  M  antibody  titres  in  the  presence  of  negative  immunoglobulin  G titres to Epstein-Barr virus (EBV).
<!-- BOUNDARY_END type="paragraph" id="p11_text_12" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_13" page="11" char_count="206" word_count="25" breadcrumbs="Exclusion Criteria" -->
If clinical suspicion of cytomegalovirus (CMV), cytomegalovirus testing should be undertaken. Subjects  with  intestinal  mucosa  biopsy  positive  for  cytomegalovirus  at  screening  are  to  be excluded.
<!-- BOUNDARY_END type="paragraph" id="p11_text_13" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_14" page="11" char_count="162" word_count="23" breadcrumbs="Exclusion Criteria" -->
Receiving any investigational therapy or any approved therapy for investigational use within 30 days or 5 half-lives prior to Randomization (whichever is longer).
<!-- BOUNDARY_END type="paragraph" id="p11_text_14" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_15" page="11" char_count="82" word_count="11" breadcrumbs="Exclusion Criteria" -->
Currently taking any medications other than those allowed per protocol guidelines.
<!-- BOUNDARY_END type="paragraph" id="p11_text_15" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_16" page="11" char_count="141" word_count="16" breadcrumbs="Exclusion Criteria" -->
Infections (including diverticulitis) requiring treatment with antibiotics, antivirals, or antifungals within 14 days prior to Randomisation.
<!-- BOUNDARY_END type="paragraph" id="p11_text_16" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_17" page="11" char_count="32" word_count="6" breadcrumbs="Exclusion Criteria" -->
Any prior use of biologic drugs.
<!-- BOUNDARY_END type="paragraph" id="p11_text_17" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_18" page="11" char_count="45" word_count="7" breadcrumbs="Exclusion Criteria" -->
Date: 16 May 2017 Ver.1.1 Supersedes: Ver.1.0
<!-- BOUNDARY_END type="paragraph" id="p11_text_18" -->

<!-- BOUNDARY_START type="paragraph" id="p11_text_19" page="11" char_count="13" word_count="4" breadcrumbs="Exclusion Criteria" -->
Page 11 of 97
<!-- BOUNDARY_END type="paragraph" id="p11_text_19" -->